Oct 2 |
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability
|
Sep 25 |
Heron gains on FDA nod for new Zynrelef application
|
Sep 25 |
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
|
Sep 11 |
Heron Therapeutics: Zynrelef Developments Are Unlikely To Provide Relief To Investors
|
Sep 9 |
Exploring Three High Growth Tech Stocks in the United States
|
Sep 3 |
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
|
Aug 9 |
Heron Therapeutics, Inc., (HRTX) Q2 2024 Earnings Call Transcript
|
Aug 9 |
Heron Therapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
Aug 8 |
Heron Therapeutics Second Quarter 2024 Earnings: EPS Misses Expectations
|
Aug 6 |
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
|